The study summarized the outcomes of bisphosphonates and RANKL-inhibitors as supportive treatment in men with prostate cancer (PC) and bone metastases (BM). The authors recommended that a balance between the efficacy and safety of such therapies must be considered for preventing skeletal events in such patients.

This study compared the effectiveness of giving androgen deprivation therapy (ADT) before or after radiotherapy (RT) for prostate cancer (PCa). The study found that treatment with RT followed by ADT increased patient survival without the spread of the disease.

This study investigated if treating patients who have prostate cancer with androgen receptor inhibitors (ARIs) increased their risk of falling and breaking their bones. The study found that patients who received ARI were more likely to have a fall or fracture compared to other treatments.

This study investigated the quality of life after treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) with enzalutamide (Xtandi) in combination with hormone therapy. The study found that enzalutamide + hormone therapy improved the quality of life of patients, compared to hormone therapy alone.

This study investigated a possible relationship between respiratory infections and androgen deprivation therapy (ADT) used to treat prostate cancer.

Researchers concluded that the risk of developing respiratory infections increases with hormonal therapy.

This clinical trial evaluated the quality of life of men with locally advanced prostate cancer (PCa) treated with Leuprorelin and radiotherapy, with or without Zolendronic Acid (ZA). Quality of life measures improved with shorter duration of Leuprorelin treatment, regardless of combining ZA.

The study evaluated outcomes of combining cabozantinib (Cabometyx) with docetaxel (Taxotere) and prednisone (Deltasone) in treating patients with metastatic castration-resistant prostate cancer (mCRPC). The main finding was that the combination was safe and could possibly be effective in such patients.

This study examined the effectiveness of pubic bone removal on pain intensity associated with an infected pubic bone in prostate cancer survivors. Authors concluded that surgical treatment is an effective approach in providing long-term pain relief from an infected pubic bone.

This study evaluated the survival rate of patients with prostate cancer (PC) that no longer responded do hormonal therapy (castration resistant) being treated with darolutamide (Nubeqa). 

The study found that darolutamide may improve survival rates and delay the start of heavy chemotherapy in these patients.

The authors aimed to determine the impact of docetaxel on patient quality of life.